期刊文献+

辛伐他汀与左卡尼丁联合治疗高脂血症的疗效分析 被引量:1

下载PDF
导出
摘要 目的:探讨辛伐他丁与左卡尼丁联合治疗混合性高脂血症的临床疗效及安全性。方法:100例混合性高脂血症患者,随机分为辛伐他丁组(n=33,20 mg/d)、左卡尼丁组(n=32,3 g/d)和联合治疗组(n=35,辛伐他丁20 mg/d和左卡尼丁3 g/d),疗程均为4个月。观察治疗前后血脂指标的变化、达标率以及不良反应。结果:联合治疗组血脂变化最显著,血清总胆固醇(TC),低密度脂蛋白(LDL-C)和甘油三酯(TG)均下降,而血清高密度脂蛋白胆固醇(HDL-C)升高(P均<0.01)。联合治疗组TC、LDL-C、TG的达标率分别为51.4%、48.6%、57.1%,三项指标全部达标者为46.7%,明显高于单药治疗组(P<0.01)。联合治疗组不良反应发生率和单药治疗组相比差异无统计学意义(P均>0.05)。结论:辛伐他丁与左卡尼丁联合可以更全面地改善混合性高脂血症,较单药治疗更为有效,具有良好的安全性和耐受性。
出处 《现代医药卫生》 2011年第9期1325-1326,共2页 Journal of Modern Medicine & Health
  • 相关文献

参考文献5

  • 1Rosensen RS,Jangney CC.Antiatherothrombotic properties of statins[J]. JAMA, 1998,279 : 1643.
  • 2全国高胆固醇血症控制状况多中心研究协作组.高胆固醇血症临床控制状况多中心协作研究——达标率及影响因素[J].中华心血管病杂志,2002,30(2):109-114. 被引量:176
  • 3Tamai O, Matsuoka M,Itabe H,et al.Single LDL apheresis improves endotheliumdependent vasodilation inhypercholesterlemic Humans[J]. Circulation, 1997,95:76.
  • 4Heinz L,Thomas K,Jens G,et al.Effects of L-earnitine and its acetyl and propionyl esters on ATP and PCr levels of isolated rat hearts perfused without fatty acids and investigated by means of 3 IP2NMR pectroseopy[J].Mol Cell Biochem, 1999,200(1~2):93.
  • 5Snow V,Aronson MD,Hombake ER,et al.Lipid control in the management of type 2 diabetes mellitus clinical practice guideline from the American College of Physicians[J].Ann Inter Meal,2004,140:644.

二级参考文献10

  • 1Slamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol a nd risk of premature death from coronary heart disease continuous and graded ? F indings in 356,222 primary screenees of the Multiple Risk Factor Intervention Tr ial (MRFIT). JAMA, 1986,256:2823-2828.
  • 2Castelli WP, Garrison RJ,Wilson PwF, et al. Incidence of coronary heart disea se and lipoprotein cholesterol levels: the Framing ham Study. JAMA, 1986, 256:28 35-2838.
  • 3Randomized trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study(4S).Lancet,1994,344:1383 -1389.
  • 4Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary- prevention t ri al with gemfibrozil in middle-aged men with dislipidemia. Safety of treatment ,c hages in risk factors, and incidence of coronary heart disease. N Engl J Med, 1 987,317:1237-1245.
  • 5Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease wit h pravastatin in men with hypercholesterolemia. West of Scotland Coronary Preven tion Study Group. N Engl J Med,1995,333:1301-1307.
  • 6Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary e v ents with lovastatin in men and women with average cholesterol levels: results o f AFCAPS/TexCAPS. Air Force/Texas Coronary Artherosclerosis Prevention Study. JAMA .1998;279:1615-1622.
  • 7Summary of the second report of the National Cholesterol Education Program (NC EP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholestero l in Adults ( Adult Treatment Panel II Report). JAMA, 1993, 269:3015-3023.
  • 8Report of the National Cholesterol Education Program Expert Panel on Detection , Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Pan el. Arch Intern Med, 1998, 148:36-69.
  • 90 Pearson TA, Laurora I, Chu H, et al. The lipid treatment assessment project (L -TAP):a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein choles terol goals. Arch Intern Med, 2000, 160:459-467.
  • 10方圻,王钟林,宁田海,邵耕,陈在嘉,陆宗良,李健斋,林传骧,周北凡,诸骏仁,诸永康,陶萍,陶寿淇,龚兰生,顾复生,游凯,戴玉华.血脂异常防治建议[J].中华心血管病杂志,1997,25(3):169-175. 被引量:3067

共引文献175

同被引文献5

引证文献1

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部